Advent International and Warburg Pincus announced they have selected Franco Negron to be CEO of BioPharma Solutions following its proposed divestiture from Baxter International. The closing of the divestiture, which remains subject to the satisfaction of customary closing conditions, is currently expected to occur in the second half of 2023. Negron is a highly accomplished leader with nearly 30 years of experience in the pharmaceutical industry. Most recently, he served for three years as the CEO of ApiJect Systems America.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BAX:
- Baxter call volume above normal and directionally bullish
- Baxter price target lowered to $45 from $47 at Citi
- Baxter put volume heavy and directionally bearish
- Baxter price target lowered to $54 from $58 at Barclays
- Baxter price target lowered to $44 from $46 at Wells Fargo
Questions or Comments about the article? Write to editor@tipranks.com